References
- Periactin (cyproheptadine) product insert. West Point, PA: Merk & Company 1997.
- Bille B, Luvdvigsson J, Sanner G. Prophylaxis of migraine in children. Headache 1977; 17:61–63.
- Registered Pharmaceuticals in Hong Kong, Department of Health, The Government of HKSAR.
- Man CY, Cheung WL. Patient behaviour on non-accidental poisoning – a prospective study. Hong Kong J Emerg Med 2000; 7:65–72.
- Bergen SS. Appetite stimulating properties of cyproheptadine. Am J Dis Child 1964; 108:270–273.
- Peroutka SJ, Allen GS. The calcium antagonist properties of cyproheptadine: implications for antimigraine action. Neurology 1984; 34:304–309.
- Peroutka SJ. Drugs effective in the therapy of migraine. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW. Goodman & Gilman: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996: 487–502.
- Katz RJ, Rosenthal M. Adverse interaction of cyproheptadine with serotonergic antidepressants. J Clin Psychiatry 1994; 55:314–315.
- Richmond M, Seger D. Central anticholinergic syndrome in a child: a case report. J Emerg Med 1985; 3:453–456.
- Blaustein BS, Gaeta TJ, Balentine JR, Gindi M. Cyproheptadine- induced central anticholinergic syndrome in a child: a case report. Pediatr Emerg Care 1995; 11:235–237.